Comanche Biopharma
Concord, US · Founded 2020 · Delaware corporation · 6 known investors
Comanche Biopharma is a biopharmaceutical company developing an investigational siRNA medicine (CBP-4888) targeting a root cause of preterm preeclampsia in pregnant women. It focuses on evidence-based therapies for life-threatening complications of pregnancy.
BiotechFemTechHealthtech
Founders & leadership
PA
Paul AntinoriExecutive
AA
Allison AugustExecutive
MY
Michael YoungExecutive
TS
Thomas Scott JohnsonNamed on SEC filing
S
Scott
Board
BB
MM
Muzammil MansuriBoard director
KP
AL
Arthur LevinBoard director
AT
Ann TaylorBoard director
CM
Clive MeanwellBoard director
AF
Allyson FelixBoard director
Investors · 6
Reported raises · per SEC filings
Form D private placements$73.6M disclosed across 2 rounds · 2021–2023
▶$37.5MraisedJan 2024 · 7 investors · PharmaceuticalsRule 506(b)
▶$37.5MraisedJan 2024 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ann TaylorDirector
- Brendan Bulik-SullivanDirector
- Muzammil MansuriDirector
- Allison AugustExecutive Officer
- Paul AntinoriExecutive Officer
- Allyson FelixDirector
- David GrayzelDirector
- Thomas Scott JohnsonExecutive Officer, Director
- Scott GottliebDirector
- Ketan PatelDirector
- Michael YoungExecutive Officer
- Offering amount
- $75M
- Amount sold
- $37.5M
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$36.1MraisedMay 2023 · 7 investors · PharmaceuticalsRule 506(b)
▶$36.1MraisedMay 2023 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Arthur LevinDirector
- Brendan Bulik-SullivanDirector
- Muzammil MansuriDirector
- Paul AntinoriExecutive Officer
- Allison AugustExecutive Officer
- Ann TaylorDirector
- Clive MeanwellDirector
- Allyson FelixDirector
- Ketan PatelDirector
- Michael YoungExecutive Officer
- Thomas Scott JohnsonExecutive Officer, Director
- Offering amount
- $36.1M
- Amount sold
- $36.1M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapXoma NASDAQ: XOMA www.xoma.com4 shared keywordsXOMA Royalty acquires and manages royalty interests in commercial and development-stage therapeutics, operating as a biotech-focused royalty aggregator. The company provides funding and structured finance to biopharmaceutical and medical technology firms.
Medscape3 shared keywordsMedscape is an online medical information platform providing clinical news, expert perspectives, case studies, quizzes, and reference material across specialties such as cardiology, oncology, neurology, and psychiatry. It serves physicians, nurses, pharmacists, residents, and medical students.
Companies competing with Comanche Biopharma for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Comanche Biopharma do?
- Comanche Biopharma is a biopharmaceutical company developing an investigational siRNA medicine (CBP-4888) targeting a root cause of preterm preeclampsia in pregnant women. It focuses on evidence-based therapies for life-threatening complications of pregnancy.
- Who are Comanche Biopharma's investors?
- Comanche Biopharma's investors include Atlas Venture, GV (Google Ventures), Broadview Ventures, F-Prime Capital Partners, F-Prime Capital, New Enterprise Associates (NEA).
- How much funding has Comanche Biopharma raised?
- Comanche Biopharma has disclosed $73.6M raised across 2 rounds.
- Where is Comanche Biopharma headquartered?
- Comanche Biopharma is headquartered in Concord, US.